Eli Lilly and Co
(XSGO:LLYCL)
CLP
767490
-8430 (-1.09%)
Market Cap: 728.77 Tn
Enterprise Value: 755.05 Tn
PE Ratio: 86.20
PB Ratio: 50.39
GF Score: 64/100 
Eli Lilly and Co at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 30, 2022 / 05:10PM GMT
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Thank you, guys, for joining us. It's a pleasure to have Eli Lilly management join us. There's a lot to talk about.
But before we do, let me turn it over to Jake to kick things off.
Jacob S. Van Naarden
Eli Lilly and Company - Senior VP, CEO of Loxo Oncology & President of Lilly Oncology
Sure. I'm Jake Van Naarden, and I lead the oncology unit here at Lilly. And thanks to the Evercore ISI team for having us today. And maybe, David, you can just introduce yourself briefly as well.
David Hyman
Loxo Oncology, Inc. - Chief Medical Officer
David Hyman, medical oncologist by training and Chief Medical Officer for Oncology here at Loxo at Lilly.
Questions & Answers
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Excellent, excellent, excellent. Well, just to
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers